Which of the following is a potential risk associated with the use of 17-OHP during pregnancy?

The use of 17-alpha hydroxyprogesterone caproate (17-OHP) during pregnancy is primarily indicated for the prevention of preterm birth in women with a history of premature labor. While this medication is generally considered safe, it can have some associated risks. One potential risk is injection site reactions. Given that 17-OHP is usually administered via intramuscular injection, adverse effects such as pain, swelling, redness, or irritation at the injection site can occur. This reflects the local impact of the medication at the site where it is administered.

Other potential risks related to blood pressure and pre-eclampsia are not typically associated with 17-OHP. Chronic hypertension and gestational hypertension are conditions that may occur in pregnancy, but they are not directly caused by the use of 17-OHP. Pre-eclampsia, characterized by hypertension and proteinuria, involves a range of risk factors independent of 17-OHP therapy.

Therefore, the identification of injection site reactions as a risk is appropriate, as it directly relates to the method of administration of 17-OHP and reflects a common consideration in any injectable medication.